DCB BO1202

Drug Profile

DCB BO1202

Alternative Names: DCB-BO1202

Latest Information Update: 11 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GoldenMed BioTechnology
  • Developer A2 Healthcare Taiwan; GoldenMed BioTechnology
  • Class Antifibrotics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatic fibrosis

Most Recent Events

  • 07 Nov 2014 A2 Healthcare and GoldenMed Bio Technology plan a phase II trial for Hepatic fibrosis in USA and Taiwan (NCT02289300)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top